NKTX Stock Analysis: Buy, Sell, or Hold?
NKTX - Nkarta, Inc. Common Stock
$3.22
0.37 (12.98%)
▲
5d:
+15.83%
30d:
+10.65%
90d:
+47.03%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When NKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NKTX is currently trading at $3.22, which is considered extended relative to its 30-day fair value range of $2.60 to $3.08.
Technical Outlook: Technically, NKTX is in a strong uptrend. Immediate support is located at $2.32, while resistance sits at $3.34. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: NKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.33 (+252.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NKTX is in a strong uptrend. Immediate support is located at $2.32, while resistance sits at $3.34. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: NKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.33 (+252.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.60 -
$3.08
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.0%)
- BULLISH: Trading 252.0% below Wall St target ($11.33)
Trading Range Analysis
30-Day Trading Range
$2.60 -
$3.08
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.32
Resistance Level
$3.34
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.95
Wall Street Target
$11.33
(+252.0%)
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Nadir Mahmood
SELL
5649 shares
2026-01-15
Paul J Hastings
SELL
26046 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
